StemCells, Inc. (NASDAQ:STEM) today provided an update on the Company's Phase I clinical trial of its proprietary HuCNS-SC® product candidate (purified human neural stem cells).

StemCells, Inc. (NASDAQ: STEM) today announced that the Phase I clinical trial of its proprietary HuCNS-SC™ product candidate (purified human neural stem cells) has successfully completed enrollment of the low-dose cohort and will proceed to the high-dose cohort.

By Ted Sickinger, The Oregonian, Portland, Ore. Apr. 15--Oregon Health & Science University has backed away from the economic development projections that it sold to legislators between 2001 and 2003 when seeking $200 million to build a bioscience research building and recruit scientists.

By Joe Rojas-Burke and Ted Sickinge, The Oregonian, Portland, Ore. Feb.

Pacific Retirement Services, Inc. (PRS), announced